cd

CD73-IN-5 is a highly potent and selective small molecule inhibitor of CD73, demonstrating non-nucleotide characteristics. It exerts its inhibitory effects with a remarkable IC50 value of 19 nM.

HP-β-CD (HP-β-CD) is a widely used drug delivery vehicle to improve stability and bioavailability.

CD235 is a structurally similar analog of CD161. CD161 is an orally bioavailable inhibitor of BET bromodomain.

CD73-IN-1 is a CD73 inhibitor with anticancer activity.

CD80-IN-3 is a potent CD80 inhibitor and inhibits CD80/CD28 interaction (Kd: 125 nM; EC50: 630 nM).

CD161 is a potent, selective, and orally bioavailable BET bromodomain inhibitor (IC50s: 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2) with good anticancer activity.

CD2665 is an orally active antagonist of retinoic acid receptor (RAR). For RARγ and RARβ, the Kis are 110 nM and 306 nM.

CD3254 is a selective and potent retinoid X receptor-like (RXR) agonist that inhibits neuronal cell death with OGD/reoxygenation.

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Mal-β-CD, a cellular cholesterol modifier, forms a soluble inclusion complex with cholesterol.

CD 1530 is a selective and potent RARγ agonist (Kd:150 nM) with potential anticancer activity, shows insecticidal activity against Cryptobacterium hidradii nematodes, and can be used to study oral carcinogenesis.

CD2314 is a potent and subtype-selective RARβ receptor agonist with a Kd of 195 nM in S91 melanoma cells [1].

CD12681 is an effective RORγ inverse agonist, preclinical Candidate for the topical therapy of psoriasis.

CD532 hydrochloride is a potent inhibitor of Aurora A kinase, having an IC50 of 45 nM. It not only blocks the activity of Aurora A kinase but also facilitates the degradation of the protein MYCN. Furthermore, CD532 hydrochloride interacts directly with AURKA, inducing a significant conformational change. Its utility in cancer research has been demonstrated [1][2].

CD532 is A highly potent Aurora A kinase inhibitor with an IC50 value of 45 nM. CD532 can block Aurora A kinase activity, drive MYCN degradation, and can directly interact with AURKA and induce global conformational transformation. CD532 can be used to study cancer.

CD2019 is a retinoic acid receptor beta (rarbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

CD08108 is a MC1R agonist.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

CD564 is a novel selective inhibitor of RARβ/γ.

DM-β-CD (2,6-Di-O-methyl-β-cyclodextrin) is a cyclic molecule composed of seven glucose units, modified with two methyl groups at the 2 and 6 positions. It is commonly utilized as a solubilizer and carrier for poorly soluble drugs in pharmaceutical formulations. Additionally, its ability to form inclusion complexes with various guest molecules—such as aromatic compounds, pesticides, and heavy metals—makes it valuable in analytical chemistry, food science, and environmental remediation.

SBE-β-CD (Sulfobutylether-β-Cyclodextrin) is a β-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether. SBE-β-CD is widely used as a co-solvent in biological experiments.

CD-2394 is a novel synthetic retinoid compound. This compound's treatment reduces the number of cells in the G2M-phase, suggesting a slowdown in cell proliferation. Additionally, normal differentiation is inhibited, while keratin 13 expression is observed in CD-2394-treated samples, a phenomenon not seen in other treated skin samples. This indicates CD-2394 may induce an embryonic differentiation pathway distinct from normal or regenerative differentiation.

CD 3400 is an isomer of Rescimetol.

CD437 (AHPN) is a specifc Retinoic Acid Receptor γ (RARγ) agonist.